Satish Jindal appointed to lead drug discovery at Allied-Bristol Life Sciences
Satish Jindal has been appointed to lead the discovery of drug candidates from leading academic institutions at Allied-Bristol Life Sciences, a jointly-owned enterprise between Allied Minds (LSE: ALM) and US drug major Bristol-Myers Squibb (NYSE: BMY).
He recently headed Bristol-Myers Squibb’s research and development center in Bangalore, India, focusing on discovery and early development of drug candidates in several disease areas. Under Dr Jindal’s leadership, Allied-Bristol will have access to the scientific expertise from Bristol-Myers and Biocon Bristol-Myers Squibb Research and Development Center.
Dr Jindal joined Bristol-Myers Squibb in 2011 as part of the team that collaborated with Allied Minds to create Allied-Bristol Life Sciences earlier this year. Previously, he had formed and built biotech companies including Vedantra, an immunotherapy company he co-founded based on intellectual property from the Koch Institute at the Massachusetts Institute of Technology.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze